Mutation, amplification, and/or overexpression of the gene encoding MET has been observed in many tumor types, and in many cases has been associated with increased cancer aggressiveness, poor prognosis, and acquired resistance to standard therapies [6–11]. This evidence concerns the gene MET and cancer.